Individual nadir changes in HIV‐1 RNA level ‐ 324 mg biweekly · patients being treated for HIV infection
1 finding from 1 review
Antiviral response ‐ 2mg/Kg · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 2 mg/kg compared with placebo (very low certainty).
1 finding from 1 review
Antiviral response ‐ 5mg/Kg · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 5 mg/kg compared with placebo (very low certainty).
1 finding from 1 review
Antiviral response: 10 mg/kg · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 10 mg/kg compared with placebo (very low certainty).
1 finding from 1 review
Antiviral response ‐ 162 mg weekly · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 162 mg weekly compared with placebo (very low certainty).
1 finding from 1 review
Antiviral response ‐ 324 mg weekly · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 324 mg weekly compared with placebo (very low certainty).
1 finding from 1 review
Antiviral response ‐ 324 mg biweekly · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 324 mg biweekly compared with placebo (very low certainty).
1 finding from 1 review
Individual nadir changes in HIV‐1 RNA level ‐ 0.5mg/Kg · patients being treated for HIV infection
1 finding from 1 review
Individual nadir changes in HIV‐1 RNA level ‐ 2mg/Kg · patients being treated for HIV infection
1 finding from 1 review
Hospitalisation for RSV infection · patients at high risk of severe respiratory syncytial virus infection
Palivizumab leads to lower hospitalisation for RSV infection compared with placebo (high certainty).
1 finding from 1 review
Total RSV hospital days per 100 children · patients at high risk of severe respiratory syncytial virus infection
1 finding from 1 review
Incidence of admissions to the ICU · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in admission to ICU compared with motavizumab (moderate certainty).
1 finding from 1 review
Mechanical ventilation for RSV infection · patients at high risk of severe respiratory syncytial virus infection
Palivizumab leads to higher mechanical ventilation for RSV infection compared with motavizumab (high certainty).
1 finding from 1 review
Supplemental oxygen therapy for RSV infection · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in supplemental oxygen therapy for RSV infection compared with motavizumab (moderate certainty).
1 finding from 1 review
Number of children reporting any SAE · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in number of children reporting any SAE compared with motavizumab (high certainty).
1 finding from 1 review
All‐cause mortality · patients at high risk of severe respiratory syncytial virus infection
Palivizumab showed no clear difference in all‐cause mortality compared with placebo (moderate certainty).
1 finding from 1 review
Total RSV hospital days per 100 children · patients at high risk of severe respiratory syncytial virus infection
1 finding from 1 review
Incidence of admissions to the ICU · patients at high risk of severe respiratory syncytial virus infection
Palivizumab leads to lower admission to ICU compared with placebo (high certainty).
1 finding from 1 review
Mechanical ventilation for RSV infection · patients at high risk of severe respiratory syncytial virus infection
It is very uncertain whether palivizumab changes mechanical ventilation for RSV infection compared with placebo (very low certainty).
1 finding from 1 review
Supplemental oxygen therapy for RSV infection · patients at high risk of severe respiratory syncytial virus infection
1 finding from 1 review